[go: up one dir, main page]

MX2017012553A - Compuestos espirociclicos. - Google Patents

Compuestos espirociclicos.

Info

Publication number
MX2017012553A
MX2017012553A MX2017012553A MX2017012553A MX2017012553A MX 2017012553 A MX2017012553 A MX 2017012553A MX 2017012553 A MX2017012553 A MX 2017012553A MX 2017012553 A MX2017012553 A MX 2017012553A MX 2017012553 A MX2017012553 A MX 2017012553A
Authority
MX
Mexico
Prior art keywords
spirocyclic compounds
present description
compounds
spirocyclic
treating
Prior art date
Application number
MX2017012553A
Other languages
English (en)
Other versions
MX379622B (es
Inventor
Daniel Hopkins Chad
Helen Slee Deborah
Lee Severance Daniel
Bunker Kevin Duane
Kumar Sit Rakesh
Abraham Sunny
Robert Pinchman Joseph
Kahraman Mehmet
Qinhua Huang Peter
Original Assignee
Kalyra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalyra Pharmaceuticals Inc filed Critical Kalyra Pharmaceuticals Inc
Publication of MX2017012553A publication Critical patent/MX2017012553A/es
Publication of MX379622B publication Critical patent/MX379622B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente descripción, se describen compuestos espirocíclicos, junto con composiciones farmacéuticas y métodos para mejorar y/o tratar un cáncer descrito en la presente descripción con uno o más de los compuestos descritos en la presente descripción.
MX2017012553A 2015-04-03 2016-03-31 Compuestos espirociclicos MX379622B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562142946P 2015-04-03 2015-04-03
PCT/US2016/025345 WO2016161160A1 (en) 2015-04-03 2016-03-31 Spirocyclic compounds

Publications (2)

Publication Number Publication Date
MX2017012553A true MX2017012553A (es) 2018-04-11
MX379622B MX379622B (es) 2025-03-11

Family

ID=57007413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012553A MX379622B (es) 2015-04-03 2016-03-31 Compuestos espirociclicos

Country Status (25)

Country Link
US (3) US10525036B2 (es)
EP (1) EP3277690B1 (es)
JP (1) JP6737533B2 (es)
KR (1) KR20170132307A (es)
CN (1) CN107849053B (es)
AU (1) AU2016242940B2 (es)
BR (1) BR112017021194A2 (es)
CA (1) CA2981055A1 (es)
CY (1) CY1123019T1 (es)
DK (1) DK3277690T3 (es)
ES (1) ES2788160T3 (es)
HR (1) HRP20200805T1 (es)
HU (1) HUE049481T2 (es)
IL (1) IL254662B (es)
LT (1) LT3277690T (es)
MX (1) MX379622B (es)
PL (1) PL3277690T3 (es)
PT (1) PT3277690T (es)
RS (1) RS60340B1 (es)
RU (1) RU2745069C2 (es)
SG (1) SG11201707911VA (es)
SI (1) SI3277690T1 (es)
SM (1) SMT202000279T1 (es)
TW (1) TWI705067B (es)
WO (1) WO2016161160A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6833677B2 (ja) * 2014-09-17 2021-02-24 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 二環式化合物
US10525036B2 (en) 2015-04-03 2020-01-07 Recurium Ip Holdings, Llc Spirocyclic compounds
CA3037064A1 (en) * 2016-10-05 2018-04-12 Zeno Royalties & Milestones, LLC Spirocyclic compounds
KR20190087622A (ko) 2016-12-08 2019-07-24 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 질환 치료를 위한 이중 류신 지퍼 (dlk) 키나아제의 바이시클로[1.1.1]펜탄 억제제
JP2021512109A (ja) * 2018-01-31 2021-05-13 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
AU2020257301B2 (en) 2019-04-18 2025-10-23 The Johns Hopkins University Substituted 2-amino-pyrazolyl-(1,2,4)triazolo(1,5a) pyridine derivatives and use thereof
US11560366B2 (en) 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
EP2086974B1 (en) 2006-11-17 2013-07-24 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
JP5276676B2 (ja) 2008-02-21 2013-08-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である化合物
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
US8658651B2 (en) 2009-09-30 2014-02-25 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
AU2010328336B2 (en) 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
EP2751118B1 (en) 2011-08-29 2016-10-12 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
CN103130775B (zh) 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US8987264B2 (en) * 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
US9447026B2 (en) * 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
US10525036B2 (en) 2015-04-03 2020-01-07 Recurium Ip Holdings, Llc Spirocyclic compounds
CA3037064A1 (en) 2016-10-05 2018-04-12 Zeno Royalties & Milestones, LLC Spirocyclic compounds

Also Published As

Publication number Publication date
IL254662B (en) 2021-02-28
JP2018511613A (ja) 2018-04-26
CN107849053A (zh) 2018-03-27
TW201710261A (zh) 2017-03-16
RU2017133973A (ru) 2019-05-06
IL254662A0 (en) 2017-11-30
RU2017133973A3 (es) 2019-07-17
SG11201707911VA (en) 2017-10-30
MX379622B (es) 2025-03-11
EP3277690A1 (en) 2018-02-07
DK3277690T3 (da) 2020-05-04
US20180207132A1 (en) 2018-07-26
PL3277690T3 (pl) 2020-08-24
BR112017021194A2 (pt) 2019-01-08
CN107849053B (zh) 2020-10-30
HUE049481T2 (hu) 2020-09-28
KR20170132307A (ko) 2017-12-01
RU2745069C2 (ru) 2021-03-18
EP3277690B1 (en) 2020-02-26
JP6737533B2 (ja) 2020-08-12
US10493060B2 (en) 2019-12-03
AU2016242940B2 (en) 2020-11-05
US20200268714A1 (en) 2020-08-27
US10525036B2 (en) 2020-01-07
ES2788160T3 (es) 2020-10-20
EP3277690A4 (en) 2018-08-22
US20190201380A1 (en) 2019-07-04
PT3277690T (pt) 2020-03-24
HRP20200805T1 (hr) 2020-10-16
TWI705067B (zh) 2020-09-21
SMT202000279T1 (it) 2020-07-08
WO2016161160A1 (en) 2016-10-06
SI3277690T1 (sl) 2020-07-31
HK1256671A1 (en) 2019-09-27
CY1123019T1 (el) 2021-10-29
AU2016242940A1 (en) 2017-10-26
RS60340B1 (sr) 2020-07-31
LT3277690T (lt) 2020-06-10
CA2981055A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
MX2018013413A (es) Compuestos inhibidores de egfr.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
ECSP17073743A (es) Moduladores de k-ras
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2019003938A (es) Compuestos espirociclicos.
MX2017012553A (es) Compuestos espirociclicos.
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
MX369863B (es) Ciertas entidades quimicas, composiciones y metodos.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2017006283A (es) Peptidos macrociclicos utiles como inmunomoduladores.
CR20150316A (es) Compuestos y sus métodos de empleo
CO2017003005A2 (es) Anticuerpos anti-mfi2
MX2016014555A (es) Composiciones novedosas, usos y metodos para hacerlas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
MX2016015163A (es) Biomarcadores mit y metodos para su uso.